Mendelspod Podcast-logo

Mendelspod Podcast

Science Podcasts >

Mendelspod was founded in 2011 by Theral Timpson and Ayanna Monteverdi to advance life science research, connecting people and ideas. Influenced by the thinking tools developed by Eli Goldgratt, the founders bring a unique approach to media in the life sciences. With help from our advisors around the industry, Mendelspod goes beyond quick sound bites to create a space for probing conversations and deep insight into the topics and trends which shape the industry's future and therefore our future as a species.

Mendelspod was founded in 2011 by Theral Timpson and Ayanna Monteverdi to advance life science research, connecting people and ideas. Influenced by the thinking tools developed by Eli Goldgratt, the founders bring a unique approach to media in the life sciences. With help from our advisors around the industry, Mendelspod goes beyond quick sound bites to create a space for probing conversations and deep insight into the topics and trends which shape the industry's future and therefore our future as a species.
More Information

Location:

United States

Description:

Mendelspod was founded in 2011 by Theral Timpson and Ayanna Monteverdi to advance life science research, connecting people and ideas. Influenced by the thinking tools developed by Eli Goldgratt, the founders bring a unique approach to media in the life sciences. With help from our advisors around the industry, Mendelspod goes beyond quick sound bites to create a space for probing conversations and deep insight into the topics and trends which shape the industry's future and therefore our future as a species.

Language:

English


Episodes

The New World of Infectious Disease Diagnosis: Out in the Field with David Hong of Karius

12/13/2018
More
A one month old baby is admitted to a hospital with fever. This is cause for serious alarm. The child is put on broad spectrum antibiotics. The infected area is drained and a culture run to try to identify the pathogen. The cultures come back negative, the pathogen not identified.

Duration:00:21:53

California Life Science Industry Steps to New Heights - the 2019 Edition with Sara Radcliffe

12/3/2018
More
Sara Radcliffe can be happy--extra happy. She is the CEO of the California Life Sciences Association at a time when the state is breaking records, beating out every other state in category after category. Today Sara discusses a new report the organization has released along with PWC detailing our sector’s explosive growth. Jobs: check. Wages and revenue: check. VC funding: check. NIH funding: check. California leads in all. Big yaaaawn?

Duration:00:22:04

Nathan and Laura on CRISPRed Babies and Other November 2018 Stories

11/29/2018
More
What a week! And a great time to have on our expert contributors, genomicist Nathan Pearson and genetic counselor Laura Hercher, to talk about what is reportedly a first in history: babies born with a gene altered. They'll be called Lulu and Nana. So just how pissed, scared, shocked, and curious are we after three days?

Duration:00:41:41

Ellen Matloff on a New Digital Genetic Counseling Product for DTC Customers

11/15/2018
More
If Mendelspod had an annual Product of the Year award, we'd certainly be liking for 2018 the one featured today, a digital genetic counseling product for direct-to-consumer genetic testing. Hats are off to Ellen Matloff, a genetic counselor formerly at Yale who saw the DTC boom coming a few years ago, busted out of academia, started My Gene Counsel, and last month launched her first digital product.

Duration:00:28:04

Connecting the Dots for a Community of Rare Disease Patients: Terri Klein, MPS Society

11/7/2018
More
The MPS Society is a rare organization. Not just because it is an umbrella for the rare diseases that have in common lysosomal storage malfunction. But because it is one of the largest rare disease organizations in the world. Terri Klein is the CEO leading the MPS Society. She says the group has over three thousand members on their roster. This brings some strength and resources in an area where low numbers intensifies an uphill battle.

Duration:00:30:26

Keith Robison and Shawn Baker on Illumina Buyout of PacBio

11/2/2018
More
Just hours after Illumina announced their buyout of Pacific Biosciences, Theral sits down with longtime sequencing Omics Omics blogger, Keith Robison, and the Chief Science Officer at sequencing marketplace, AllSeq, Shawn Baker, to discuss the news which has taken the industry by surprise. A special thanks to our sponsor, Sage Science, and the quick decision on this show.

Duration:00:24:48

October 2018 Review with Nathan and Laura: ASHG Does Race, Parents Do Gene Therapy, Unsung Demons

10/31/2018
More
As an election nears, the question of race and genetics has been front and center. It even prompted ASHG to take the unusual step of making a group wide statement. The three of us agree: scientists should talk more about the race question with non-scientists. Two papers in Tech Review this month show that the world of people buying cures and disease prevention through gene editing isn’t around the corner, it’s here. Now what about those who can’t afford it? One of the papers was written by...

Duration:00:36:24

A Point-of-Care CBC Test Based on a Few Drops of Blood—Is This the Real Thing? with Danny Levner, Sight Diagnostics

10/25/2018
More
Time is health. Take certain blood cancers, for instance. When a patient is seen in a doctor’s office, they are then sent to a central lab for testing, and the results can take a few days. With blood cancer patients, these few days can be vital. For years a holy grail in diagnostics has been to get diagnostic tests to the point-of-care based on just a few drops of the patient’s blood that could give immediate results.

Duration:00:25:11

It’s a Gold Rush in Single Cell Genomics, Says Joachim Schultze, U of Bonn

10/15/2018
More
The title says it all here. Herr Professor Schultze directs a major facility that he calls a single cell genomics platform. They have most of the single cell technologies available and partner with labs from all over the world on research. Advances in single cell technologies are changing basic research and also delivering results for translational work in everything from immunology to obesity. “Biology will never be the same again,” says Joachim.

Duration:00:26:49

A Market Solution for Biospecimen Quality Standards with Matt McLoughlin, Scientist.com

10/1/2018
More
We ran a series this summer highlighting one of the major issues in biomedical research: that the collection, storage, and procurement of biospecimen samples lacks any across-the-board governing standards. Various institutions adopt their own regulations resulting in a checkerboard of quality assurance, and by extension, an unknown effect on the outcomes of research. Our first guest called it “garbage in, garbage out.” (See links below.) This should send shudders through anyone doing...

Duration:00:30:24

September 2018 with Nathan and Laura: Studying the Same Genes and the Matt Fender Story

9/28/2018
More
And here we were thinking it was a slow month! We have two big stories today: first this philosophy of biology question about whether it’s a bad thing that we’ve been stuck circling the wagons ‘round the same ole genes. Is it just an economic question? Or is it that these are the most active genes, and so we need a meritocracy, as Nathan puts forth?

Duration:00:35:20

Single Cell Sequencing Tailor Made for Nephrology, Says Vivek Bhalla, Stanford

9/20/2018
More
Vivek Bhalla is used to the question, what’s a nephrologist? When we admitted we’d never had one on the program, he made his own admission, saying that the kinds of people who became nephrologists are the kinds of people who don’t seek out the limelight. But Vivek, an assistant professor of medicine at Stanford, is changing that and speaking out on behalf of his profession. And he’s very excited about what single cell sequencing has done for the study of the kidney.

Duration:00:21:46

It’s the Social Factors, Stupid! Lisa Suennen on Healthcare, Her Career, Digital Health Investing, and . . . Just Being Herself

9/13/2018
More
She's been a highly sought after venture funder and knowledge broker in the field of digital health. STAT News wrote that upwards of 1,500 pitches crossed her desk last year at GE Ventures. But as of a couple weeks ago, it's a desk at which she's no longer sitting. So what's she up to next?

Duration:00:27:49

Concerned About DTC Test Quality? Ask Two Questions, Says Daryl Pritchard, PMC

9/5/2018
More
We like talking to the folks at the Personalized Medicine Coalition (PMC). They have many stakeholders and multifaceted speakers on a wide range of topics. Recently they’re open to talking more about DTC testing—as are most of the traditional diagnostics community. (In our most popular program of the year, CEO of Invitae, Sean George said back in May that the clinical community must “coop” with the rapidly growing DTC movement.)

Duration:00:28:45

August 2018 Review with Nathan and Laura: The polygenic month

8/31/2018
More
It’s our first show back after the summer break, and nothing has got us all buzzing about genomics again like a polygenic risk score. It even has Laura Hercher talking about the Human Genome Project doing some delivering, god forbid. CRISPR has had a rough summer. But still . . . it is CRISPR. Is Burning Man still cool, we were asked last weekend. Don't know. Don't care. We asked back, is 23andMe still cool?

Duration:00:29:42

An International Perspective on How to Improve Biobanking with Kirstin Goldring

8/21/2018
More
For the next episode in our summer series on human tissue sample quality and biobanking, we turn to a veteran biobanker in the U.K. who managed several projects there including the U.K. Parkisons’ Disease Society Brain Bank at Imperial College. Today we talk to Kirstin Goldring, Principal Scientist at Astra Zeneca where she’s in charge of Human Biological Sample Strategy and Governance. Kirstin is a counselor at the European Society for Biopreservation and Biobanking and also a member of...

Duration:00:20:12

A Seqster Preview with Founder Ardy Arianpour

8/16/2018
More
As long as we’ve been doing clinical genetics, the goal has been to marry up the genetic data with phenotypic data in the electronic medical records. This has been achieved with some success and with a few of the best genetic markers at some of the leading healthcare providers: Geisinger, Rady Children's, Brigham and Women’s—to name a few. But it hasn’t happened at scale, at least not in this country. Some of the national health services around the world are making the dream more of a...

Duration:00:23:49

Detective Stories from the Genomic War Room with Ramesh Hariharan

7/26/2018
More
A book like this only comes around once in a while—one never knows from which corner. This time it was written by the CTO of a next gen sequencing data analytics company. “Every one of these cases was intense. It was just so fascinating that I had to put it down in a book and tell the story. There’s so much in biology that boggles your mind and makes you wonder.”

Duration:00:31:13

Should Biobanking Come Under CLIA? Shannon McCall, Duke

7/17/2018
More
When former President Obama’s team released the paperwork for what’s become the All of Us Research Program, in the part about biobanking, the wording specified that the biobanks applying for the grants be “CLIA compliant.”

Duration:00:27:43

Pharma Stepping Up, Footing the Bill for Genetic Testing & Counseling: Jordanna Mora, Alnylam

6/12/2018
More
It seems to be human nature to value and pay up to hundreds of thousands of dollars for a little white pill that we can drop on the floor--and granted, can do wonders for us, but we want to pay nothing or very little to be told what is wrong with us so that we might know which little white pill to use in the first place.

Duration:00:15:24